WO 2016/038550 Al 17 March 2016 (17.03.2016) P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2016/038550 Al 17 March 2016 (17.03.2016) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/038550 Al 17 March 2016 (17.03.2016) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/113 (2010.01) A61K 31/713 (2006.01) kind of national protection available): AE, AG, AL, AM, G01N 33/574 (2006.01) A61P 35/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB2015/056902 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, >September 2015 (09.09.2015) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (25) Filing Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62/049,004 11 September 2014 ( 11.09.2014) US kind of regional protection available): ARIPO (BW, GH, 62/13 1,437 11 March 2015 ( 11.03.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant (for all designated States except US) : NO- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, VARTIS AG [—/CH]; Lichtstrasse 35, CH-4056 Basel DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (CH). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (72) Inventors; and GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicants (for US only): MAVRAKIS, Konstantinos John [US/US]; Novartis Institutes for BioMedical Re Declarations under Rule 4.17: search, Inc., 250 Massachusetts Avenue, Cambridge, MA — as to applicant's entitlement to apply for and be granted a 02139 (US). MCDONALD, Earl, III [US/US]; Novartis patent (Rule 4.1 7(H)) Institutes for BioMedical Research, Inc., 250 Massachu setts Avenue, Cambridge, MA 02139 (US). STEGMEI- Published: ER, Frank Peter [US/US]; Novartis Institutes for Bio — with international search report (Art. 21(3)) Medical Research, Inc., 250 Massachusetts Avenue, Cam bridge, MA 02139 (US). — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (74) Agent: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel amendments (Rule 48.2(h)) (CH). © © v o (54) Title: INHIBITION OF PRMT5 TO TREAT MTAP -DEFICIENCY-RELATED DISEASES (57) Abstract: The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is MTAP -deficient and/or MTA-accumulating and thus amenable to therapeutic o treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided. INHIBITION OF PRMT5 TO TREAT MTAP-DEFICIENCY-RELATED DISEASES TECHNICAL FIELD [001] The present invention provides novel compositions, as well as diagnostic and treatment methods for diseases related to MTAP deficiency and/or MTA accumulation, including, but not limited to, types of cancer. BACKGROUND [002] Many types of cancer are associated with a poor prognosis. [003] Pancreatic cancer is associated with a poor long-term survival rate of only 10% to 15% after resection. Patients with positive microscopic resection margins have a worse survival. The median survival was 19.7 months with chemotherapy versus 14.0 months without. See, e.g., Neoptolemos et al. 2001 Ann. Surg. 234: 758-768. [004] Mesothelioma is a rare form of cancer that develops from cells of the mesothelium, the protective lining that covers many of the internal organs of the body. Mesothelioma is most commonly caused by exposure to asbestos. While mesothelioma is still relatively rare, rates have increased in the last twenty years. One study showed a survival rate of only 38% at 2 years and 15% at 5 years (median 19 months). See, e.g., Sugarbaker et al. 1999 J. Thorac. Card. Surg. 117: 54-65. [005] Glioblastoma is the most common and most aggressive malignant primary brain tumor in humans. It involves glial cells and accounts for half of all brain tumor cases and a fifth of all intracranial tumors. Treatment can involve surgery, radiation and chemotherapy. However, median survival with treatment is only 15 months. [006] An unmet medical need exists for new treatments for these and other types of cancer. [007] There is an increasing body of evidence that suggests a patient’s genetic profile can be determinative to a patient’s responsiveness to a therapeutic treatment. Given the numerous therapies available to an individual having cancer, a determination of the genetic factors that influence, for example, response to a particular drug, could be used to provide a patient with a personalized treatment regime. Such personalized treatment regimens offer the potential to maximize therapeutic benefit to the patient while minimizing related side effects that can be associated with alternative and less effective treatment regimens. SUMMARY OF THE INVENTION [008] According to a first aspect of the invention, methods for inhibiting the proliferation of cells that are MTAP-deficient and/or MTA-accumulating, including types of glioblastoma and other cancer cells, are provided. The methods comprise the step of administering, to a subject in need thereof, a PRMT5 inhibitor in an amount that is effective to inhibit the proliferation of the MTAP-deficient and/or MTA-accumulating cells, including cancer cells. In some embodiments, the MTAP-deficient and/or MTA-accumulating cells are also CDKN2A-deficient. Cells can be determined to be MTAP deficient by techniques known in the art, for example, immunohistochemistry utilizing an anti-MTAP antibody or derivative thereof, and/or genomic sequencing, and/or nucleic acid hybridization or amplification utilizing at least one probe or primer comprising a sequence of at least 12 contiguous nucleotides (nt) of the sequence of MTAP provided in SEQ ID NO: 98, wherein the primer is no longer than about 30 nt, about 50 nt, or about 100 nt in length. Cells are determined to be MTA overproducing or MTA accumulating by techniques known in the art; methods for detecting MTA include, as a non-limiting example, liquid chromatography– electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS). [009] In one embodiment, the invention provides use of a molecule that inhibits the cellular function of the PRMT5 protein for the treatment of a disease associated with MTAP deficiency and/or MTA accumulation, including, but not limited to, a cancer, including, for example, but not limited to: glioblastoma, bladder cancer, pancreatic cancer, mesothelioma, melanoma, lung squamous, lung adenocarcinoma, diffuse large B-cell lymphoma, leukemia, head and neck cancer, and cancers of the kidney, breast, endometrium, urinary tract, liver, soft tissue, pleura and large intestine. [0010] Also provided is a use of a molecule that inhibits the cellular function of the PRMT5 protein for the manufacture of a medicament for treating a disease associated with MTAP deficiency and/or MTA accumulation, including, but not limited to, a cancer, including, for example, but not limited to: glioblastoma, bladder cancer, pancreatic cancer, mesothelioma, melanoma, lung squamous, lung adenocarcinoma, diffuse large B-cell lymphoma, leukemia, head and neck cancer, and cancers of the kidney, breast, endometrium, urinary tract, liver, soft tissue, pleura and large intestine. [0011] The PRMT5 inhibitor may be selected from the group consisting of: a RNA inhibitor (e.g., a RNAi agent), a CRISPR, a TALEN, a zinc finger nuclease, an mRNA, an antibody or derivative thereof, a chimeric antigen receptor T cell (CART) or a low molecular weight (LMW) compound. [0012] The PRMT5 inhibitor may be selected from the group consisting of: an antibody or derivative thereof, or a low molecular weight compound. In some embodiments, the antibody or a derivative thereof binds to a HLA-peptide complex comprising a peptide having the sequence of any of SEQ ID NOs: 101-158. [0013] According to an embodiment, the method according to the first aspect comprises administering to a subject in need thereof, a PRMT5 inhibitor in combination with a second therapeutic agent. [0014] In an embodiment, the second therapeutic agent is an anti-cancer agent, anti- allergic agent, anti-nausea agent (or anti-emetic), pain reliever, or cytoprotective agent. [0015] According to one embodiment, the second therapeutic agent is an anti-cancer agent selected from the list consisting of: an HDAC inhibitor, fluorouracil (5-FU) and irinotecan, a HDM2 inhibitor, a purine analogue, 6-thioguanine, 6-mercaptopurine, and CDK4 inhibitors, including, but not limited to, LEE011, and inhibitors of HDM2i, PI3K/mTOR-I, MAPKi, RTKi (EGFRi, FGFRi, METi, IGFiRi, JAKi, and WNTi. [0016] According to a second aspect of the invention, a method of determining if a subject afflicted with a cancer will respond to therapeutic treatment with a PRMT5 inhibitor is provided. The method comprises the steps: a) evaluating a test sample obtained from said subject for MTAP deficiency and/or MTA accumulation relative to a reference normal or non-cancerous control sample, wherein MTAP deficiency and/or MTA accumulation in the test sample indicates that the subject will respond to therapeutic treatment with a PRMT5 inhibitor; wherein the method comprises the following optional steps: b) determining the level of PRMT5 in the subject, wherein steps a) and b) can be performed in any order; c) administering a therapeutically effective amount of a PRMT5 inhibitor to the subject; and d) determining the level of PRMT5 in the subject following step c), wherein a decrease in the level of PRMT5 is correlated with the inhibition of the proliferation of the cancer, and wherein steps c) and d) are performed after steps a) and b).
Recommended publications
  • Methylthioadenosine Phosphorylase (MTAP) Is Frequent in High-Grade Gliomas; Nevertheless, It Is Not Associated with Higher Tumor Aggressiveness
    cells Article 0 Loss of 5 -Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness Weder Pereira de Menezes 1, Viviane Aline Oliveira Silva 1 , Izabela Natália Faria Gomes 1 , Marcela Nunes Rosa 1 , Maria Luisa Corcoll Spina 1 , Adriana Cruvinel Carloni 1, Ana Laura Vieira Alves 1 , Matias Melendez 1, Gisele Caravina Almeida 2, Luciane Sussuchi da Silva 1 , Carlos Clara 3, Isabela Werneck da Cunha 4, Glaucia Noeli Maroso Hajj 4 , Chris Jones 5, Lucas Tadeu Bidinotto 1,6,7 and Rui Manuel Reis 1,8,9,* 1 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] (W.P.d.M.); [email protected] (V.A.O.S.); [email protected] (I.N.F.G.); [email protected] (M.N.R.); [email protected] (M.L.C.S.); [email protected] (A.C.C.); [email protected] (A.L.V.A.); [email protected] (M.M.); [email protected] (L.S.d.S.); [email protected] (L.T.B.) 2 Department of Pathology, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] 3 Department of Neurosurgery, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] 4 A.C Camargo Cancer Center, São Paulo, São Paulo 015.080-10, Brazil; [email protected] (I.W.d.C.); [email protected] (G.N.M.H.) 5 Institute of Cancer Research, London SW7 3RP, UK; [email protected] 6 Barretos School of Health Sciences, Dr.
    [Show full text]
  • The Two Tort Dit U Nonton Un Mountin
    THETWO TORT DIT USU 20180010132A1NONTONUN MOUNTIN ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0010132 A1 MAVRAKIS et al. ( 43 ) Pub . Date : Jan . 11 , 2018 ( 54 ) INHIBITION OF PRMT5 TO TREAT Publication Classification MTAP - DEFICIENCY- RELATED DISEASES (51 ) Int . CI. C12N 15 / 113 ( 2010 .01 ) (71 ) Applicant : NOVARTIS AG , Basel (CH ) A61K 45 / 06 ( 2006 . 01) ( 72 ) Inventors : Konstantinos John MAVRAKIS , A61K 31 / 7088 (2006 . 01 ) Boston , MA (US ) ; Earl Robert COZK 16 / 40 ( 2006 .01 ) MCDONALD , III , Wayland , MA (US ) ; A61K 39 /395 ( 2006 . 01 ) Frank Peter STEGMEIER , Acton , GOIN 33 /574 (2006 . 01 ) A61K 39 / 00 ( 2006 .01 ) MA (US ) (52 ) U . S . CI. CPC . .. C12N 15 / 1137 ( 2013 .01 ) ; A61K 39 /3955 ( 73 ) Assignee : Novartis AG , Basel (CH ) ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; GOIN 33 /574 ( 2013. 01 ) ; C12Y 201/ 01 (2013 .01 ) ; ( 21 ) Appl. No. : 15 /510 , 542 A61K 31 /7088 (2013 .01 ) ; CO7K 16 / 40 ( 2013 .01 ) ; A61K 2039 /505 (2013 . 01 ) ; C12N ( 22 ) PCT Filed : Sep . 9 , 2015 2310 / 14 (2013 . 01 ) ; C12N 2320 / 31 ( 2013 .01 ) ; ( 86 ) PCT No .: PCT/ IB2015 /056902 CO7K 2317/ 76 ( 2013 .01 ) $ 371 (c ) ( 1 ) , (57 ) ABSTRACT ( 2 ) Date : Mar. 10 , 2017 The invention provides novel personalized therapies , kits , transmittable forms of information and methods for use in treating patients having cancer , wherein the cancer is Related U . S . Application Data MTAP - deficient and / or MTA -accumulating and thus ame (60 ) Provisional application No . 62/ 131 ,437 , filed on Mar . nable to therapeutic treatment with a PRMT5 inhibitor. Kits , 11 , 2015 , provisional application No .
    [Show full text]
  • Specific Targeting of MTAP-Deleted Tumors with a Combination of 2 ′-Fluoroadenine and 5′-Methylthioadenosine
    Published OnlineFirst May 29, 2018; DOI: 10.1158/0008-5472.CAN-18-0814 Cancer Translational Science Research Specific Targeting of MTAP-Deleted Tumors with a Combination of 20-Fluoroadenine and 50-Methylthioadenosine Baiqing Tang, Hyung-Ok Lee, Serim S. An, Kathy Q. Cai, and Warren D. Kruger Abstract Homozygous deletion of the methylthioadenosine phos- dependent manner, shifting the IC50 concentration by one to phorylase (MTAP) gene is a frequent event in a wide variety of three orders of magnitude. However, in mice, MTA protected human cancers and is a possible molecular target for therapy. against toxicity from 2FA but failed to protect against 6TG. One potential therapeutic strategy to target MTAP-deleted Addition of 100 mg/kg MTA to 20 mg/kg 2FA entirely reversed tumors involves combining toxic purine analogues such as the toxicity of 2FA in a variety of tissues and the treatment was 60-thioguanine (6TG) or 20-fluoroadenine (2FA) with the well tolerated by mice. The 2FAþMTA combination inhibited À MTAP substrate 50-deoxy-50-methylthioadenosine (MTA). The tumor growth of four different MTAP human tumor cell lines þ rationale is that excess MTA will protect normal MTAP cells in mouse xenograft models. Our results suggest that 2FAþMTA from purine analogue toxicity because MTAP catalyzes the may be a promising combination for treating MTAP-deleted conversion of MTA to adenine, which then inhibits the con- tumors. version of purine base analogues into nucleotides. However, À in MTAP tumor cells, no protection takes place because Significance: Loss of MTAP occurs in about 15% of all adenine is not formed.
    [Show full text]
  • CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas Are Correlated with Loss of P16 Protein Expression and Poor Survival
    Modern Pathology (2010) 23, 531–538 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 531 CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival Alyssa M Krasinskas1, David L Bartlett2, Kathleen Cieply1 and Sanja Dacic1 1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA and 2Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Homozygous deletion of CDKN2A (p16) is one of the most common genetic alterations in pleural mesotheliomas, occurring in up to 74% of cases. MTAP resides in the same gene cluster of the 9p21 region and is co-deleted in the majority of CDKN2A deleted cases. This study examines the genetic alterations in peritoneal mesotheliomas, which may have a different pathogenesis than their pleural counterparts. Twenty-six cases of peritoneal mesotheliomas in a triplicate tissue microarray were studied. Dual-color fluorescence in situ hybridization was performed with CDKN2A and MTAP locus-specific probes. Nine of 26 (35%) peritoneal mesotheliomas had homozygous deletion of CDKN2A; MTAP was co-deleted in every case. All cases with CDKN2A deletions had loss of p16 protein expression; five cases had loss of p16 protein without evidence of CDKN2A deletions. All patients with CDKN2A deletions were men (P, NS) and were significantly older (mean, 63 years) than the patients with no deletions (mean, 52 years) (P ¼ 0.033, t-test). An association with asbestos exposure could not be proved in this study. Similar to pleural mesotheliomas, patients with CDKN2A deletions and loss of p16 protein expression had worse overall and disease-specific survival (P ¼ 0.010 and 0.006, respectively; Kaplan–Meier log rank).
    [Show full text]
  • Methylthioadenosine Phosphorylase at 1.7 Å Resolution Provides Insights Into Substrate Binding and Catalysis Todd C Appleby1, Mark D Erion2 and Steven E Ealick3*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Research Article 629 The structure of human 5′-deoxy-5′-methylthioadenosine phosphorylase at 1.7 Å resolution provides insights into substrate binding and catalysis Todd C Appleby1, Mark D Erion2 and Steven E Ealick3* Background: 5′-Deoxy-5′-methylthioadenosine phosphorylase (MTAP) Addresses: 1Section of Biochemistry, Molecular and catalyzes the reversible phosphorolysis of 5′-deoxy-5′-methylthioadenosine Cell Biology, Cornell University, Ithaca, NY 14853, USA and 2Metabasis Therapeutics, Inc., 9390 Town (MTA) to adenine and 5-methylthio-D-ribose-1-phosphate. MTA is a by-product Center Drive, San Diego, California 92121, USA of polyamine biosynthesis, which is essential for cell growth and proliferation. and 3Department of Chemistry and Chemical This salvage reaction is the principle source of free adenine in human cells. Biology, Cornell University, Ithaca, NY 14853, USA. Because of its importance in coupling the purine salvage pathway to polyamine *Corresponding author. biosynthesis MTAP is a potential chemotherapeutic target. Email: [email protected] Results: We have determined the crystal structure of MTAP at 1.7 Å resolution Key words: methylthioadenosine phosphorylase, using multiwavelength anomalous diffraction phasing techniques. MTAP is a multiwavelength anomalous diffraction, purine trimer comprised of three identical subunits. Each subunit consists of a single nucleoside phosphorylase, salvage pathway α β β / domain containing a central eight-stranded mixed sheet, a smaller five- Received: 18 January 1999 stranded mixed β sheet and six α helices. The native structure revealed the Revisions requested: 17 February 1999 presence of an adenine molecule in the purine-binding site.
    [Show full text]
  • Concordance of Copy Number Loss and Down-Regulation of Tumor Suppressor Genes: a Pan-Cancer Study Min Zhao1 and Zhongming Zhao2,3,4,5*
    The Author(s) BMC Genomics 2016, 17(Suppl 7):532 DOI 10.1186/s12864-016-2904-y RESEARCH Open Access Concordance of copy number loss and down-regulation of tumor suppressor genes: a pan-cancer study Min Zhao1 and Zhongming Zhao2,3,4,5* From The International Conference on Intelligent Biology and Medicine (ICIBM) 2015 Indianapolis, IN, USA. 13-15 November 2015 Abstract Background: Tumor suppressor genes (TSGs) encode the guardian molecules to control cell growth. The genomic alteration of TSGs may cause tumorigenesis and promote cancer progression. So far, investigators have mainly studied the functional effects of somatic single nucleotide variants in TSGs. Copy number variation (CNV) is another important form of genetic variation, and is often involved in cancer biology and drug treatment, but studies of CNV in TSGs are less represented in literature. In addition, there is a lack of a combinatory analysis of gene expression and CNV in this important gene set. Such a study may provide more insights into the relationship between gene dosage and tumorigenesis. To meet this demand, we performed a systematic analysis of CNVs and gene expression in TSGs to provide a systematic view of CNV and gene expression change in TSGs in pan-cancer. Results: We identified 1170 TSGs with copy number gain or loss in 5846 tumor samples. Among them, 207 TSGs tended to have copy number loss (CNL), from which fifteen CNL hotspot regions were identified. The functional enrichment analysis revealed that the 207 TSGs were enriched in cancer-related pathways such as P53 signaling pathway and the P53 interactome.
    [Show full text]
  • Gene Deletion Chemoselectivity: Codeletion of the Genes for P16(INK4), Methylthioadenosine Phosphorylase, and the Alpha
    University of Massachusetts Medical School eScholarship@UMMS Open Access Articles Open Access Publications by UMMS Authors 1996-03-01 Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy Zhi-Hao Chen University of Massachusetts Medical School Et al. Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/oapubs Part of the Cancer Biology Commons, and the Oncology Commons Repository Citation Chen Z, Zhang H, Savarese TM. (1996). Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy. Open Access Articles. Retrieved from https://escholarship.umassmed.edu/oapubs/371 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. [CANCERRESEARCH56, 1083-1090, March1, 19961 Gene Deletion Chemoselectivity: Codeletion of the Genes for p16@'@4, Methylthioadenosine Phosphorylase, and the a- and @-Interferons in Human Pancreatic Cell Carcinoma Lines and Its Implications for Chemotherapy' Zhi-Hao Chen, Hongyang Zhang, and Todd M. Savarese2 Cancer Center, University of Massachusetts Medical Center, Worcester, Massachusetts 01655 ABSTRACT Loss of these “innocentbystander―genes may be significant, because loss of the expression of the proteins encoded by these genes may alter Pancreatic carcinoma cells lines are known to have a high incidence of cellular physiology and, as a consequence, the sensitivity of these homozygous deletion of the candidate tumor suppressor genepl6 (MTSJ/ cells to certain therapeutic agents.
    [Show full text]
  • Content Based Search in Gene Expression Databases and a Meta-Analysis of Host Responses to Infection
    Content Based Search in Gene Expression Databases and a Meta-analysis of Host Responses to Infection A Thesis Submitted to the Faculty of Drexel University by Francis X. Bell in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2015 c Copyright 2015 Francis X. Bell. All Rights Reserved. ii Acknowledgments I would like to acknowledge and thank my advisor, Dr. Ahmet Sacan. Without his advice, support, and patience I would not have been able to accomplish all that I have. I would also like to thank my committee members and the Biomed Faculty that have guided me. I would like to give a special thanks for the members of the bioinformatics lab, in particular the members of the Sacan lab: Rehman Qureshi, Daisy Heng Yang, April Chunyu Zhao, and Yiqian Zhou. Thank you for creating a pleasant and friendly environment in the lab. I give the members of my family my sincerest gratitude for all that they have done for me. I cannot begin to repay my parents for their sacrifices. I am eternally grateful for everything they have done. The support of my sisters and their encouragement gave me the strength to persevere to the end. iii Table of Contents LIST OF TABLES.......................................................................... vii LIST OF FIGURES ........................................................................ xiv ABSTRACT ................................................................................ xvii 1. A BRIEF INTRODUCTION TO GENE EXPRESSION............................. 1 1.1 Central Dogma of Molecular Biology........................................... 1 1.1.1 Basic Transfers .......................................................... 1 1.1.2 Uncommon Transfers ................................................... 3 1.2 Gene Expression ................................................................. 4 1.2.1 Estimating Gene Expression ............................................ 4 1.2.2 DNA Microarrays ......................................................
    [Show full text]
  • Network Analysis of Micrornas, Transcription Factors, Target Genes and Host Genes in Human Anaplastic Astrocytoma
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 12: 437-444, 2016 Network analysis of microRNAs, transcription factors, target genes and host genes in human anaplastic astrocytoma LUCHEN XUE1,2, ZHIWEN XU2,3, KUNHAO WANG2,3, NING WANG2,3, XIAOXU ZHANG1,2 and SHANG WANG2,3 1Department of Software Engineering; 2Key Laboratory of Symbol Computation and Knowledge Engineering of the Ministry of Education; 3Department of Computer Science and Technology, Jilin University, Changchun, Jilin 130012, P.R. China Received December 2, 2014; Accepted January 29, 2016 DOI: 10.3892/etm.2016.3272 Abstract. Numerous studies have investigated the roles TP53. PTEN and miR-21 have been observed to form feedback played by various genes and microRNAs (miRNAs) in loops. Furthermore, by comparing and analyzing the pathway neoplasms, including anaplastic astrocytoma (AA). However, predecessors and successors of abnormally expressed genes the specific regulatory mechanisms involving these genes and miRNAs in three networks, similarities and differences and miRNAs remain unclear. In the present study, associated of regulatory pathways may be identified and proposed. In biological factors (miRNAs, transcription factors, target genes summary, the present study aids in elucidating the occurrence, and host genes) from existing studies of human AA were mechanism, prevention and treatment of AA. These results combined methodically through the interactions between may aid further investigation into therapeutic approaches for genes and miRNAs, as opposed to studying one or several. this disease. Three regulatory networks, including abnormally expressed, related and global networks were constructed with the aim Introduction of identifying significant gene and miRNA pathways. Each network is composed of three associations between miRNAs Astrocytoma is a tumor of the astrocytic glial cells and the targeted at genes, transcription factors (TFs) regulating most common type of central nervous system (CNS) neoplasm, miRNAs and miRNAs located on their host genes.
    [Show full text]
  • Expression of MTAP Inhibits Tumor-Related Phenotypes in HT1080 Cells Via a Mechanism Unrelated to Its Enzymatic Function
    INVESTIGATION Expression of MTAP Inhibits Tumor-Related Phenotypes in HT1080 Cells via a Mechanism Unrelated to Its Enzymatic Function Baiqing Tang,* Yuwaraj Kadariya,* Yibai Chen,* Michael Slifker,† and Warren D. Kruger*,1 *Cancer Biology Program and †Biostatistics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 ABSTRACT Methylthioadenosine Phosphorylase (MTAP) is a tumor suppressor gene that is frequently KEYWORDS deleted in human cancers and encodes an enzyme responsible for the catabolism of the polyamine byprod- cell mobility and uct 59deoxy-59-methylthioadenosine (MTA). To elucidate the mechanism by which MTAP inhibits tumor migration formation, we have reintroduced MTAP into MTAP-deleted HT1080 fibrosarcoma cells. Expression of MTAP suppressor genes resulted in a variety of phenotypes, including decreased colony formation in soft-agar, decreased migration, methionine decreased in vitro invasion, increased matrix metalloproteinase production, and reduced ability to form tumors in severe combined immunodeficiency mice. Microarray analysis showed that MTAP affected the expression of genes involved in a variety of processes, including cell adhesion, extracellular matrix inter- action, and cell signaling. Treatment of MTAP-expressing cells with a potent inhibitor of MTAP’s enzymatic activity (MT-DADMe-ImmA) did not result in a MTAP2 phenotype. This finding suggests that MTAP’s tumor suppressorfunctionisnotthesameasitsknownenzymaticfunction.Toconfirm this, we introduced a catalytically inactive version of MTAP, D220A, into HT1080 cells and found that this mutant was fully capable of reversing the soft agar colony formation, migration, and matrix metalloproteinase phenotypes. Our results show that MTAP affects cellular phenotypes in HT1080 cells in a manner that is independent of its known enzymatic activity. Methylthioadenosine phosphorylase (MTAP) is a widely expressed Schmid et al.
    [Show full text]
  • Lack of Methylthioadenosine Phosphorylase Expression In
    Imaging, Diagnosis, Prognosis Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy Silvia Marce¤ ,1Olga Balague¤ ,1Luis Colomo,1Antonio Martinez,1Sylvia Ho« ller,3 Neus Villamor,1 Francesc Bosch,2 German Ott,3 Andreas Rosenwald,3 Lorenzo Leoni,4 Manel Esteller,5 Mario F. Fraga,5 Emili Montserrat,2 Dolors Colomer,1and Elias Campo1 Abstract Purpose: To determine the methylthioadenosine phosphorylase (MTAP) gene alterations in mantle cell lymphoma (MCL) and to investigate whether the targeted inactivation of the alterna- tive de novo AMP synthesis pathway may be a useful therapeutic strategy in tumors with inacti- vation of this enzyme. Experimental Design: MTAP gene deletion and protein expression were studied in 64 and 52 primary MCL, respectively, and the results were correlated with clinical behavior. Five MCL cell lines were analyzed for MTAP expression and for the in vitro sensitivity to L-alanosine, an inhibitor of adenylosuccinate synthetase, and hence de novo AMP synthesis. Results: No protein expression was detected in 8 of 52 (15%) tumors and one cell line (Granta 519). Six of these MTAP negative tumors and Granta 519 cell line had a codeletion of MTAP and p16 genes; one case showed a deletion of MTAP, but not p16 , and one tumor had no deletions in neither of these genes. Patients with MTAP deletions had a significant shorter overall survival (mean, 16.1 months) than patients with wild-type MTAP (mean, 63.6 months; P < 0.0001). L-Alanosine induced cytotoxicity and activation of the intrinsic mitochondrial- dependent apoptotic pathway in MCL cells.
    [Show full text]
  • Distinct Deletions of Chromosome 9P Associated with Melanoma Versus Glioma, Lung Cancer, and Leukemia 1
    [CANCER RESEARCH54, 344--348, January 15,1994] Advances in Brief Distinct Deletions of Chromosome 9p Associated with Melanoma versus Glioma, Lung Cancer, and Leukemia 1 Aaron Coleman, Jane W. Fountain, Tsutomu Nobori, Olufunmilayo I. Olopade, Gavin Robertson, David E. Housman, and Tracy G. Lugo 2 Division of Biomedical Sciences, University of California, Riverside, California 92521 [A. C., G. R., T. G. L.]; Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [J. W. F, D. E. H.]; Department of Medicine, University of California, San Diego, California 92093 [I. N.]; and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 [0. L 0.] Abstract lines using probes that detect the IFN-a and D9S126 loci confirms the location of the telomeric 9p breakpoint in line AH between IFN-a and Deletions of DNA on chromosome 9p21-22 are frequently observed in MTAP and suggests that the analogous breakpoint in line FF resides cells derived from melanomas, gliomas, non-small cell lung cancers, and in a location centromeric to MTAP. acute lymphoblastic leukemia. The minimal deletion shared by the latter three cancers extends from the interferon-a locus towards the centromere; Materials and Methods its centromeric end is flanked by the gene encoding methylthioadenosine phosphorylase. We have determined that the telomeric end of the minimal Cell Lines and Culture Conditions. The origin of the human malignant homozygous deletion shared by two melanoma cell lines does not include melanoma cell lines FF (SK-Mel-133) and AH (SK-Mel-13) has been de- the methylthioadenosine phosphorylase locus.
    [Show full text]